HR Execs on the Move


 
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.azitrainc.com
  • 400 Farmington Ave CB126
    Farmington, CT USA 06032
  • Phone: 860.679.4292

Executives

Name Title Contact Details

Similar Companies

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MB Research Laboratories

MB Research Laboratories is a Spinnerstown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ZIOPHARM Oncology

ZIOPHARM Oncology is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SenesTech

Left unchecked, two base rats, a male and a female, can result in 15,000 descendants in about 12 months. It`s easy to see how quickly this can lead to infestations and even population rebounds if just two rats are left behind after a knockdown program. That`s where we come in. We`re SenesTech, the rat fertility experts and the makers of ContraPest®, the first and only EPA-registered rat fertility restrictor impacting both male and female rats. We make it possible to target both ends of the lifecycle—birth and death—by adding fertility control to your integrated pest management (IPM) solution. Controlling the birth rate with ContraPest will magnify the success of your existing IPM protocols. ContraPest is the one-of-a-kind, innovative technology that targets the reproductive capabilities of both male and female Norway and roof rats. Sweet and fatty, it`s highly palatable like a “milkshake” rats can`t get enough of. By using ContraPest, you can reduce the rat population and keep it down because ContraPest works!

Merck Life Science

Created by the 1975 merger of Sigma Chemical Company and Aldrich Chemical Company, Sigma-Aldrich since grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000 at the time of its acquisition by Merck.